We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
-17.89%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$977M
AUM Growth
-$359M
Cap. Flow
-$135M
Cap. Flow %
-13.86%
Top 10 Hldgs %
55.77%
Holding
68
New
11
Increased
16
Reduced
16
Closed
21

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$38.9M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$27.6M
3
BKD icon
Brookdale Senior Living
BKD
+$21.8M
4
AET
Aetna Inc
AET
+$20.5M
5
MOH icon
Molina Healthcare
MOH
+$19.5M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$61.6M
2
WCG
Wellcare Health Plans, Inc.
WCG
+$44M
3
DPLO
DIPLOMAT PHARMACY, INC.
DPLO
+$38.2M
4
INSM icon
Insmed
INSM
+$25.3M
5
UNH icon
UnitedHealth
UNH
+$22M

Sector Composition

Rank Sector Weight
1 Healthcare 77.22%
2 Financials 2.61%
3 Communication Services 2.08%
4 Consumer Staples 1.23%
5 Industrials 0.67%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLVS
26
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$11.5M 1.18%
+600,000
New +$12.7M
CTMX icon
27
CytomX Therapeutics
CTMX
$725M
$9.41M 0.96%
729,699
-8,657
-1% -$120K
OXFD
28
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$8.68M 0.89%
876,088
+15,800
+2% +$162K
CFMS
29
DELISTED
Conformis, Inc. Common Stock
CFMS
$8.52M 0.87%
31,694
+26,666
+530% +$7.06M
CRL icon
30
Charles River Laboratories
CRL
$11B
$8.34M 0.85%
109,806
-12,594
-10% -$932K
NVRO
31
DELISTED
NEVRO CORP.
NVRO
$7.35M 0.75%
130,571
-284,627
-69% -$16.8M
NVTA
32
DELISTED
Invitae Corporation
NVTA
$6.75M 0.69%
660,129
– –
HTWR
33
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
$6.75M 0.69%
+214,771
New +$7.27M
PGND
34
DELISTED
PRESS GANEY HOLDINGS INC COM STK (DE)
PGND
$6.56M 0.67%
218,214
-21,402
-9% -$609K
GWPH
35
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$5.94M 0.61%
+82,300
New +$4.52M
EHTH icon
36
eHealth
EHTH
$42.9M
$3.96M 0.41%
+421,742
New +$4.19M
PFE icon
37
Pfizer
PFE
$143B
$3.67M 0.38%
130,485
– –
SNDX icon
38
Syndax Pharmaceuticals
SNDX
$1.88B
$3.5M 0.36%
+263,000
New +$3.31M
DRRX
39
DELISTED
DURECT Corp
DRRX
$3.14M 0.32%
232,714
-30,128
-11% -$384K
PRQR icon
40
ProQR Therapeutics
PRQR
$253M
$2.7M 0.28%
552,713
-4,480
-0.8% -$22.8K
FATE icon
41
Fate Therapeutics
FATE
$294M
$2.68M 0.27%
1,486,980
-884,021
-37% -$1.82M
IHF icon
42
iShares US Healthcare Providers ETF
IHF
$1.18B
$551K 0.06%
22,600
– –
BPMC
43
DELISTED
Blueprint Medicines
BPMC
$488K 0.05%
27,055
-249,632
-90% -$4.33M
SIOX
44
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$115K 0.01%
+1,250
New +$133K
AUPH icon
45
Aurinia Pharmaceuticals
AUPH
$1.96B
$58K 0.01%
19,710
+3,100
+19% +$7.5K
CCXI
46
DELISTED
ChemoCentryx, Inc.
CCXI
$25K ﹤0.01%
10,000
-53,189
-84% -$194K
ADVM
47
DELISTED
Adverum Biotechnologies
ADVM
– –
-2,424
Closed -$231K
AXDX
48
DELISTED
Accelerate Diagnostics
AXDX
– –
-1,000
Closed -$215K
CARM
49
DELISTED
Carisma Therapeutics
CARM
– –
-43,793
Closed -$2.64M
DBVT
50
DBV Technologies
DBVT
$820M
– –
-799
Closed -$290K
1
2
3

Similar funds

KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Redmile Group's Q1 2016 Portfolio in Review

As of Q1 2016, Redmile Group held 68 positions worth $977M, down 27% from $1.34B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Redmile Group withdrew a net $135M in Q1 2016, closing 21 positions and reducing 16 holdings. Its most notable exit was Teva Pharmaceuticals, an estimated $61.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, up from 77% a quarter earlier, followed by Financials and Communication Services.

Against the trend, Redmile Group opened a new position in BioMarin Pharmaceuticals worth $39.4M.

  • Redmile Group's largest Q1 2016 buy was BioMarin Pharmaceuticals: 478,287 shares worth $39.4M.
  • Redmile Group added most to Clovis Oncology, Inc. in Q1 2016, an estimated $27.6M increase.
  • Redmile Group's biggest Q1 2016 reduction was NEVRO CORP., cutting an estimated $16.8M.
  • Redmile Group fully exited Teva Pharmaceuticals in Q1 2016, selling an estimated $61.6M.
  • Redmile Group's ten largest holdings make up 56% of its $977M portfolio in Q1 2016.
  • Redmile Group opened 11 new positions and closed 21 in Q1 2016.
  • Redmile Group's portfolio value fell 27% quarter-over-quarter to $977M.

Based on Redmile Group's 13F filing for Q1 2016, filed 16 May 2016.